Evommune shares fall sharply after trial fails to meet primary endpoint

Source Summary

Evommune's stock declined significantly following the announcement that a clinical trial failed to achieve its primary endpoint. The trial result represents a setback for the company's development program.

Why it matters

Failed clinical trial endpoints directly impact a biotech company's ability to advance drug candidates and generate future revenue.

Read the Source

• Investing.com ↗